Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EBT (2018 - 2025)

Neurogene (NGNE) has disclosed EBT for 5 consecutive years, with -$21.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 3.15% year-over-year to -$21.0 million, compared with a TTM value of -$86.2 million through Sep 2025, down 47.85%, and an annual FY2024 reading of -$74.1 million, down 40.81% over the prior year.
  • EBT was -$21.0 million for Q3 2025 at Neurogene, up from -$23.2 million in the prior quarter.
  • Across five years, EBT topped out at -$17.1 million in Q1 2024 and bottomed at -$23.2 million in Q2 2025.